Cargando…

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study

To study the differences in the immune response to SARS-CoV-2 infection compared to the response to vaccination, we characterized the humoral immune kinetics of these situations. In this prospective longitudinal study, we followed unvaccinated COVID-19-recovered individuals (n = 130) and naïve, two-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joseph, Gili, Cohen, Carmit, Rubin, Carmit, Murad, Havi, Indenbaum, Victoria, Asraf, Keren, Weiss-Ottolenghi, Yael, Segal-Lieberman, Gabriella, Kreiss, Yitshak, Lustig, Yaniv, Regev-Yochay, Gili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384358/ https://www.ncbi.nlm.nih.gov/pubmed/37512801 http://dx.doi.org/10.3390/microorganisms11071628

Ejemplares similares

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
por: Joseph, Gili, et al.
Publicado: (2022)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
por: Nir, Omer, et al.
Publicado: (2022)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study
por: Lustig, Yaniv, et al.
Publicado: (2021)

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
por: Bergwerk, Moriah, et al.
Publicado: (2021)

Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
por: Gilboa, Mayan, et al.
Publicado: (2023)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
por: Barda, Noam, et al.
Publicado: (2022)

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
por: Regev-Yochay, Gili, et al.
Publicado: (2023)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses
por: Gozlan, Yael, et al.
Publicado: (2021)

The Sheba Medical Center healthcare workers' children's school: can we open schools safely?
por: Kriger, Or, et al.
Publicado: (2021)

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
por: Peled, Yael, et al.
Publicado: (2022)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
por: Shacham-Shmueli, Einat, et al.
Publicado: (2022)

Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant
por: Peled, Yael, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
por: Lipsitch, Marc, et al.
Publicado: (2021)

Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis
por: Indenbaum, Victoria, et al.
Publicado: (2020)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
por: Peled, Yael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1kr0ul9vfq2m5jct4fln50ss74